Search company, investor...

Predict your next investment

Lucas Venture Group company logo
Venture Capital
FINANCE | Investment Firms & Funds
lucasvg.com

Investments

25

Portfolio Exits

5

Funds

4

About Lucas Venture Group

Lucas Venture Group is a venture capital firm making investments of $250,000-$3,000,000 in companies. The industries that Lucas Venture Group focuses on include social media, consumer web, medical devices, software, analytics and communications infrastructure.

Headquarters Location

545 Middlefield Road Ste 220

Menlo Park, California, 94025,

United States

650-543-3300

Want to inform investors similar to Lucas Venture Group about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Lucas Venture Group News

Prellis Biologics Raises $35M in Series C Funding

Aug 10, 2022

Prellis Biologics , a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding. The round, which brings funding to date to $64.5m, was led by  Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. The company intends to use the funds to expand its proprietary, first-in-class human immune system-based drug discovery and development platform, EXIS™ (Externalized Human Immune System). Led by CEO Michael Nohaile, Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. Prellis’ proprietary platform Externalized Immune System, EXIS™, precisely reproduces the human immune response through the creation of lymph node organoids (LNOs). With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications including antibody discovery, immunogenicity assessment and tumor-immune models. Dr. Nohaile joins from Generate Biomedicines and succeeds Prellis Bio founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat. The company will also add two new board members: Lei Meng, Senior Therapeutics Analyst of Avidity Partners, and Nobel Prize winner James Rothman, PhD the Sterling Professor of Cell Biology at Yale University. Earlier this year, Prellis Bio announced collaboration and licensing option agreements with Sanofi and Bristol Myers Squibb. FinSMEs 10/08/2022

Lucas Venture Group Investments

25 Investments

Lucas Venture Group has made 25 investments. Their latest investment was in Allermi as part of their Pre-Seed on September 9, 2022.

CBI Logo

Lucas Venture Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/8/2022

Pre-Seed

Allermi

$1.25M

Yes

1

7/6/2022

Series C

Prellis Biologics

$35M

Yes

3

9/16/2021

Seed VC - II

Tailor-ED

Yes

1

4/26/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/20/2019

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/8/2022

7/6/2022

9/16/2021

4/26/2021

11/20/2019

Round

Pre-Seed

Series C

Seed VC - II

Series B

Seed VC

Company

Allermi

Prellis Biologics

Tailor-ED

Subscribe to see more

Subscribe to see more

Amount

$1.25M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

1

10

10

Lucas Venture Group Portfolio Exits

5 Portfolio Exits

Lucas Venture Group has 5 portfolio exits. Their latest portfolio exit was Sunbasket on January 31, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/31/2022

Merger

$99M

3

12/20/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/1/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/30/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/10/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/31/2022

12/20/2021

6/1/2015

1/30/2015

1/10/2013

Exit

Merger

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Lucas Venture Group Fund History

4 Fund Histories

Lucas Venture Group has 4 funds, including Lucas Venture Group V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/24/2016

Lucas Venture Group V

Early-Stage Venture Capital

Open

$2.02M

1

10/12/2015

Lucas Venture Group XVII

$99M

10

10/12/2015

Lucas Venture Group IV

Subscribe to see more

Subscribe to see more

$99M

10

9/23/2011

Lucas Venture Group IX LLC

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

2/24/2016

10/12/2015

10/12/2015

9/23/2011

Fund

Lucas Venture Group V

Lucas Venture Group XVII

Lucas Venture Group IV

Lucas Venture Group IX LLC

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Amount

$2.02M

$99M

$99M

$99M

Sources

1

10

10

10

Lucas Venture Group Team

2 Team Members

Lucas Venture Group has 2 team members, including current Founder, Managing Director, Donald A. Lucas.

Name

Work History

Title

Status

Donald A. Lucas

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Donald A. Lucas

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.